Evidence map›Paper›PMID 40075375›Full record

ArticleBMC cancer2025

Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.

Pingdong Cao, Xiao Jia, Xi Wang, Liyuan Fan, Zheng Chen, Yuanyuan Zhao, Jian Zhu, Qiang Wen

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pingdong CaoDepartment of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, China.
Xiao JiaSchool of Control Science and Engineering, Shandong University, Jinan, China.
Xi WangDepartment of Radiation Oncology, Stanford University, Palo Alto, 94305, USA.
Liyuan FanDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, 250021, China.
Zheng ChenDepartment of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, China.
Yuanyuan ZhaoDepartment of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, China.
Jian ZhuDepartment of Radiation Physics and Technology, Shandong Cancer Hospital and Institute, Jinan, 250021, China.
Qiang WenDepartment of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, China. wq890425@126.com.

Funding

Jinan Science and Technology Clinical Medicine Innovation Plan 20225011Natural Science Foundation of Shandong Province ZR2024MH268Shandong Medical Association Clinical Research Fund- -Qilu Special Project YXH2022ZX02196Shandong Province Medical Staff Science and Technology Innovation Program SDYWZGKCJH2022018
6 · The paper itself

Abstract

backgroundEarly and accurate identification of epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients with brain metastases is critical for guiding targeted therapy. This study aimed to develop a deep learning radiomics model utilizing multi-sequence magnetic resonance imaging (MRI) to differentiate between EGFR mutant type (MT) and wild type (WT).

methodsIn this retrospective study, 288 NSCLC patients with confirmed brain metastases were enrolled, including 106 with EGFR MT and 182 with EGFR WT. All patients were randomly divided into a training dataset (75%) and a validation dataset (25%). Radiomics and deep learning features were extracted from the brain metastatic lesions using contrast-enhanced T1-weighted (T1CE) and T2-weighted (T2W) MRI images. Features extraction and selection were performed using the least absolute shrinkage and selection operator (LASSO) and ResNet34. The predictive performance of the signatures for EGFR mutation status was assessed using receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses.

resultsNo significant differences were found between the training and validation datasets. A four-feature radiomics signature (RS) demonstrated excellent predictive accuracy for EGFR MT, with α-binormal-based and empirical AUCs of 0.931 (95% CI: 0.880-0.940) and 0.926 (95% CI: 0.877-0.933), respectively. Incorporating deep learning signature (DLS) further enhanced the model's performance, achieving α-binormal-based and empirical AUCs of 0.943 (95% CI: 0.921-0.965) and 0.938 (95% CI: 0.914-0.962) in the training dataset. These findings were confirmed in the validation dataset, with AUCs of 0.936 (95% CI: 0.917-0.955) and 0.921 (95% CI: 0.901-0.941), demonstrating robust and consistent predictive performance.

conclusionsThe multi-sequence MRI-based deep learning radiomics model exhibited high efficacy in predicting EGFR mutation status in NSCLC patients with brain metastases. This approach, which integrates advanced radiological features with deep learning techniques, offers a non-invasive and accurate method for determining EGFR mutation status, potentially guiding personalized treatment decisions in clinical practice.

Indexed as

Adenocarcinoma of LungBrain NeoplasmsDeep LearningLung NeoplasmsMagnetic Resonance ImagingMutationAdultAgedErbB ReceptorsFemaleHumansMaleMiddle AgedRadiomicsRetrospective StudiesROC CurveEGFR protein, humanErbB ReceptorsBrain metastasisDeep learningEpidermal growth factor receptorMagnetic resonance imagingRadiomics

Identifiers

PMID40075375
PMCPMC11899356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.